It is a broadly described auditors’ report of Beximco Pharmaceuticals Limited in the year of 2017. Gross profit of the company rose to Taka. 7,184,881,623 million in 2017. Profit after tax also increased to Taka. 2,226,695,124 million in 2017, compared to Taka. 2,948,053,854 million in 2015-2016. Profit before Contribution to WPPF & Welfare Funds Taka. 3,036,055,741 million in 2017. Accounts receivable of Taka. 289,820,128 equivalents to US$ 3,618,229 as on 30 June 2017 (on 30-06-2016 Tk. 107,075,699 equivalent to US$ 1,372,765) against export sales.
The directors recommended 12.5% cash dividend (i.e. Tk. 1.25 per share) for the year 2016-17. The dividend proposal is subject to shareholders’ approval at the forthcoming annual general meeting. These financial statements are presented in Bangladesh Taka (Taka/Tk/BDT) which is the company’s functional currency. All financial information presented in Taka has been rounded off to the nearest Taka.
More Annual Report of Beximco Pharmaceuticals Limited :
- Annual Report 2001 of Beximco Pharmaceuticals Limited
- Annual Report 2002 of Beximco Pharmaceuticals Limited
- Annual Report 2003 of Beximco Pharmaceuticals Limited
- Annual Report 2004 of Beximco Pharmaceuticals Limited
- Annual Report 2005 of Beximco Pharmaceuticals Limited
- Annual Report 2006 of Beximco Pharmaceuticals Limited
- Annual Report 2007 of Beximco Pharmaceuticals Limited
- Annual Report 2008 of Beximco Pharmaceuticals Limited
- Annual Report 2009 of Beximco Pharmaceuticals Limited
- Annual Report 2010 of Beximco Pharmaceuticals Limited
- Annual Report 2011 of Beximco Pharmaceuticals Limited
- Annual Report 2012 of Beximco Pharmaceuticals Limited
- Annual Report 2013 of Beximco Pharmaceuticals Limited
- Annual Report 2014 of Beximco Pharmaceuticals Limited
- Auditors’ Report 2015 of Beximco Pharmaceuticals Limited
- Annual Report 2016 of Beximco Pharmaceuticals Limited
- Auditors’ Report 2017 of Beximco Pharmaceuticals Limited
